Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea

/in , , , /by

Botanix has announced that sublicensee Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea.  

Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive range of prescription and over-the-counter products. The launch of ECCLOCK is expected to occur in the first quarter of 2026, and the product will be manufactured at Kaken’s Shizuoka plant in Japan. 

Click to read the ASX release.  

Botanix Releases Annual Report

/in , , , /by

The Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability.

View Report.

Dr Patricia Walker Joins Botanix Board

/in , , , /by

Botanix welcomes Patricia Walker, MD, PhD, to the Board. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies and the insights of a working dermatologist. She has led drug development for numerous key dermatology products, including Sofdra™ (sofpironium), from a preclinical asset to Phase 3 before its acquisition by Botanix.

View ASX Release

Botanix investor presentation at Canaccord Genuity event

/in , , , , /by

Botanix Chief Executive Officer Dr Howie McKibbon will be a featured presenter at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, which attracts institutional fund managers from around the world, and some of the most promising global growth companies, including those in the healthcare and life sciences sectors, will present during the event.

Click to view the ASX Release.

Botanix Releases Quarterly Reports

/in , , /by

The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q4 FY2025 have been released. During the quarter, Botanix raised A$40m in capital, established a loan facility of up to the euro equivalent of US$30 million, and ended the quarter with A$64.9m cash. With operating costs stable and revenues expected to rise, Botanix is well funded to support Sofdra™ (sofpironium) to profitability.

Click to view reports.

Botanix signs debt facility with Kreos Capital

/in , , /by

Botanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million).

Kreos Capital is a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. The new debt facility will be available to Botanix for working capital purposes for the commercialisation of Sofdra™, as well as other platform expansion opportunities. H.C. Wainwright & Co. acted as origination, structuring and placement agent for the transaction.

Click to read the ASX release.

Botanix included in ASX 300 Index

/in , , , /by

Botanix Pharmaceuticals is very pleased to announce that the Company will be included in the S&P/ASX 300 Index as part of the March 2025 quarterly rebalance.

The S&P/ASX 300, or simply, ASX 300, is a stock market index of Australian stocks listed on the Australian Securities Exchange (ASX). The ASX 300 index covers the large-cap, mid-cap, and small-cap components of the S&P/ASX Index Series.

To be considered for inclusion, a company must meet a minimum market capitalization, typically around A$100 million, based on average daily market cap over the last six months, and have sufficient liquidity; meaning the stock must be actively traded in adequate volume to be considered institutionally investable. The index is regularly reviewed, and companies are added or removed to rebalance twice annually to reflect changes in market capitalization and liquidity.

Click here to see the ASX announcement

Botanix Releases Quarterly Reports

/in , , , /by

Quarterly Activity Report and 4C Quarterly Cash Flow Report released. Botanix held A$48.36 million cash with no debt, which will fund operations through the transition to a revenue generating pharmaceutical company with full commercial launch of Sofdra™ in Q1 2025. View Report.

First Sofdra™ prescriptions as commercialization ramps up

/in , , , /by

First prescriptions for Sofdra™ (sofpironium) topical gel, 12.45% have shipped to patients after having successfully been diagnosed via telemedicine and cleared insurance approvals. Following sales force deployment, a wider digital program will begin in Q2 2025.

View release.

Botanix presentation at Bell Potter Healthcare Conference

/in , , , /by

Botanix Founder and Board Executive Director Matt Callahanwill be a featured presenter at the Bell Potter Healthcare Conference 2024 on Tuesday, 19 November. A copy of the presentation being used is attached to the ASX press release.

View ASX release.